Know Cancer

forgot password

Parallel (Randomized) Phase II Evaluation of ARQ 197 and ARQ 197 in Combination With Erlotinib in Papillary Renal Cell Carcinoma

Phase 2
Open (Enrolling)
Childhood Renal Cell Carcinoma, Recurrent Renal Cell Cancer, Stage III Renal Cell Cancer, Stage IV Renal Cell Cancer, Type 1 Papillary Renal Cell Carcinoma, Type 2 Papillary Renal Cell Carcinoma

Thank you

Trial Information

Parallel (Randomized) Phase II Evaluation of ARQ 197 and ARQ 197 in Combination With Erlotinib in Papillary Renal Cell Carcinoma


I. To assess the response rate (confirmed complete and partial response) of patients with
locally advanced or metastatic papillary renal cell carcinoma treated with either ARQ 197
(tivantinib) or ARQ 197 combined with erlotinib (erlotinib hydrochloride).


I. To assess the progression free survival (PFS) of patients with locally advanced or
metastatic papillary renal cell carcinoma treated with either ARQ 197 or ARQ 197 combined
with erlotinib.

II. To assess the safety and tolerability of ARQ 197 therapy and ARQ 197 combined with

III. To bank tissue specimens for future use and once funding is obtained to evaluate the
expression of tissue correlative biomarkers such as hepatocyte growth factor receptor
(c-MET) and epidermal growth factor receptor (EGFR), and to perform exploratory correlation
with clinical outcomes.

IV. To descriptively assess the role of prior treatment on outcome.

OUTLINE: Patients are randomized to 1 of 2 treatment arms.

ARM I: Patients receive tivantinib orally (PO) twice daily (BID) on days 1-28.

ARM II: Patients receive tivantinib PO BID and erlotinib hydrochloride PO once daily (QD) on
days 1-28.

In both arms, courses repeat every 28 days in the absence of disease progression or
unacceptable toxicity.

After completion of study treatment, patients are followed up every 3 months for 1 year and
then every 6 months for up to 2 years.

Inclusion Criteria:

- Patients must have histologically or cytologically confirmed papillary histology
renal cell carcinoma which is metastatic, or locally advanced and unresectable; mixed
histologies will be allowed provided that they contain >= 50% of the papillary

- Patients must have measurable disease, defined as at least one lesion that can be
accurately measured in at least one dimension; x-rays, scans or physical examinations
used for tumor measurement must have been completed within 28 days prior to
registration; x-rays, scans or physical examinations for non-measurable disease must
have been completed within 42 days prior to registration; all disease must be
assessed and documented on the Baseline Tumor Assessment form

- Patients with metastatic disease who have a resectable primary tumor and are deemed a
surgical candidate may have undergone resection; at least 28 days must have elapsed
since surgery and patient must have recovered from any adverse effects of surgery

- Patients with a history of brain metastases who are asymptomatic and have not
received steroid therapy in the 14 days prior to registration are eligible;
anti-seizure medications are allowed provided they are non-enzyme inducing (e.g.
topiramate, levetiracetam, gabapentin)

- Patients may have received up to one prior systemic therapy for advanced or
metastatic renal cell carcinoma; patients must not have received a MET inhibitor or
erlotinib as prior therapy; at least 21 days must have elapsed since completion of
prior systemic therapy, 42 days for nitrosoureas or mitomycin C; patients must have
recovered from all associated toxicities at the time of registration

- Patients may have received prior radiation therapy, but must have measurable disease
outside the radiation port; at least 21 days must have elapsed since completion of
prior radiation therapy; patients must have recovered from all associated toxicities
at the time of registration

- Patients must be offered the opportunity to participate in specimen banking for
future translational medicine studies

- Patients must have a Zubrod performance status of 0-2

- White blood cell (WBC) >= 2,000/mcL

- Absolute neutrophil count (ANC) >= 1,000/mcL

- Platelet count >= 75,000/mcL

- Serum bilirubin =< 1.5 x institutional upper limits of normal (ULN)

- Serum glutamic oxaloacetic transaminase (SGOT)/aspartate aminotransferase (AST) and
serum glutamic pyruvate transaminase (SGPT)/alanine aminotransferase (ALT) must be =<
1.5 x the institutional ULN unless the liver is involved with the tumor, in which
case serum transaminase (SGOT/SGPT) must be =< 5 x the institutional ULN

- Serum creatinine must be =< 2 x the institutional ULN

- Sodium, potassium and calcium must be obtained within 14 days prior to registration

- Patients with a known history of the following corneal diseases are not eligible: dry
eye syndrome, Sjogren's syndrome, keratoconjunctivitis sicca, exposure keratopathy,
Fuchs' dystrophy or other active disorders of cornea

- Patients known to be human immunodeficiency virus (HIV)-positive and receiving
combination anti-retroviral therapy are not eligible

- Patients must be able to take oral medications; patients must not have
gastrointestinal tract disease resulting in an inability to take oral medication or a
requirement for intravenous (IV) alimentation, prior surgical procedures affecting
absorption, or active peptic ulcer disease; patients with intractable nausea or
vomiting are not eligible

- Patients must not be receiving or planning to receive any other investigational

- Patients must not be pregnant or nursing; women/men of reproductive potential must
have agreed to use an effective contraceptive method; a woman is considered to be of
"reproductive potential" if she has had menses at any time in the preceding 12
consecutive months; in addition to routine contraceptive methods, "effective
contraception" also includes heterosexual celibacy and surgery intended to prevent
pregnancy (or with a side-effect of pregnancy prevention) defined as a hysterectomy,
bilateral oophorectomy or bilateral tubal ligation; however, if at any point a
previously celibate patient chooses to become heterosexually active during the time
period for use of contraceptive measures outlined in the protocol, he/she is
responsible for beginning contraceptive measures

- No other prior malignancy is allowed except for the following: adequately treated
basal cell or squamous cell skin cancer, in situ cervical cancer, adequately treated
stage I or II cancer from which the patient is currently in complete remission, or
any other cancer from which the patient has been disease-free for 5 years

- All patients must be informed of the investigational nature of this study and must
sign and give written informed consent

- As a part of the Oncology Patient Enrollment Network (OPEN) registration process the
treating institution's identity is provided in order to ensure that the current
(within 365 days) date of institutional review board approval for this study has been
entered in the system

Type of Study:


Study Design:

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

Response rate (confirmed complete response [CR] or partial response [PR]), determined according to Response Evaluation Criteria in Solid Tumors (RECIST)

Outcome Time Frame:

Up to 3 years

Safety Issue:


Principal Investigator

Przemyslaw Twardowski

Investigator Role:

Principal Investigator

Investigator Affiliation:

Southwest Oncology Group


United States: Food and Drug Administration

Study ID:




Start Date:

August 2012

Completion Date:

Related Keywords:

  • Childhood Renal Cell Carcinoma
  • Recurrent Renal Cell Cancer
  • Stage III Renal Cell Cancer
  • Stage IV Renal Cell Cancer
  • Type 1 Papillary Renal Cell Carcinoma
  • Type 2 Papillary Renal Cell Carcinoma
  • Carcinoma
  • Carcinoma, Renal Cell



University of Iowa Hospitals and Clinics Iowa City, Iowa  52242
University of Mississippi Medical Center Jackson, Mississippi  39216-4505
Fox Chase Cancer Center Philadelphia, Pennsylvania  19111
University of Washington Medical Center Seattle, Washington  98195-6043
Hurley Medical Center Flint, Michigan  48503
Genesys Hurley Cancer Institute Flint, Michigan  48503
Fairview Ridges Hospital Burnsville, Minnesota  55337
Hutchinson Area Health Care Hutchinson, Minnesota  55350
United Hospital St. Paul, Minnesota  55102
Ridgeview Medical Center Waconia, Minnesota  55387
Loyola University Medical Center Maywood, Illinois  60153
Rapid City Regional Hospital Rapid City, South Dakota  57709
Via Christi Regional Medical Center Wichita, Kansas  67214
University of Oklahoma Health Sciences Center Oklahoma City, Oklahoma  73104
Group Health Cooperative Seattle, Washington  98112
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium Seattle, Washington  98109
Cancer Center of Kansas - Chanute Chanute, Kansas  66720
Cancer Center of Kansas - Dodge City Dodge City, Kansas  67801
Cancer Center of Kansas - Newton Newton, Kansas  67114
Cancer Center of Kansas - Salina Salina, Kansas  67042
Cancer Center of Kansas - Wellington Wellington, Kansas  67152
Associates in Womens Health Wichita, Kansas  67203
Cancer Center of Kansas - Winfield Winfield, Kansas  67156
Adena Regional Medical Center Chillicothe, Ohio  54601
Grady Memorial Hospital Delaware, Ohio  43015
Fairfield Medical Center Lancaster, Ohio  43130
Harborview Medical Center Seattle, Washington  98104
Cancer Care Northwest - Spokane South Spokane, Washington  99202
Methodist Estabrook Cancer Center Omaha, Nebraska  68114-4199
University Medical Center of Southern Nevada Las Vegas, Nevada  89102
Saint Francis Medical Center Cape Girardeau, Missouri  63701
Grandview Hospital Dayton, Ohio  45405
Mercy Hospital Coon Rapids, Minnesota  55433
Saint Joseph Mercy Hospital Ann Arbor, Michigan  48106
Fairview-Southdale Hospital Edina, Minnesota  55435
Abbott-Northwestern Hospital Minneapolis, Minnesota  55407
Regions Hospital Saint Paul, Minnesota  55101
Saint Francis Regional Medical Center Shakopee, Minnesota  55379
Rice Memorial Hospital Willmar, Minnesota  56201
Miami Valley Hospital Dayton, Ohio  45409
Cancer Center of Kansas - Fort Scott Fort Scott, Kansas  66701
Cancer Center of Kansas-Independence Independence, Kansas  67301
Lawrence Memorial Hospital Lawrence, Kansas  66044
Menorah Medical Center Overland Park, Kansas  66209
North Kansas City Hospital Kansas City, Missouri  64116
Research Medical Center Kansas City, Missouri  64132
Saint Luke's East - Lee's Summit Lee's Summit, Missouri  64086
Heartland Regional Medical Center Saint Joseph, Missouri  64506
Wayne Hospital Greenville, Ohio  45331
Knox Community Hospital Mount Vernon, Ohio  43050
Wenatchee Valley Medical Center Wenatchee, Washington  98801-2028
Genesys Regional Medical Center Grand Blanc, Michigan  48439-8066
Greene Memorial Hospital Xenia, Ohio  45385
Providence Medical Center Kansas City, Kansas  66112
Hennepin County Medical Center Minneapolis, Minnesota  
University of Rochester Rochester, New York  14642
Glens Falls Hospital Glens Falls, New York  12801
Saint Alphonsus Regional Medical Center Boise, Idaho  83706
Wayne State University Detroit, Michigan  48202
Riverside Methodist Hospital Columbus, Ohio  43214
Licking Memorial Hospital Newark, Ohio  43055-2899
Cancer Center of Kansas - McPherson McPherson, Kansas  67460
Columbus CCOP Columbus, Ohio  43206
Wichita CCOP Wichita, Kansas  67214-3882
Huntsman Cancer Institute/University of Utah Salt Lake City, Utah  84112
Metro-Minnesota CCOP St. Louis Park, Minnesota  
Lakeview Hospital Stillwater, Minnesota  55082
New Ulm Medical Center New Ulm, Minnesota  56073
Saint Francis Hospital and Medical Center Hartford, Connecticut  06105
Good Samaritan Regional Medical Center Mt. Vernon, Illinois  62864
Saint Francis Hospital and Health Centers Beech Grove, Indiana  46107
Reid Hospital and Health Care Services Richmond, Indiana  47374
Mercy Medical Center-Sioux City Sioux City, Iowa  51104
Saint Luke's Regional Medical Center Sioux City, Iowa  51104
Cancer Center of Kansas - El Dorado El Dorado, Kansas  67042
Cancer Center of Kansas-Kingman Kingman, Kansas  67068
Cancer Center of Kansas - Parsons Parsons, Kansas  67357
Cancer Center of Kansas - Pratt Pratt, Kansas  67124
Cancer Center of Kansas-Wichita Medical Arts Tower Wichita, Kansas  67208
Cancer Center of Kansas - Main Office Wichita, Kansas  67214
Michigan Cancer Research Consortium Community Clinical Oncology Program Ann Arbor, Michigan  48106
Oakwood Hospital Dearborn, Michigan  48123
Saint John Hospital and Medical Center Detroit, Michigan  48236
Allegiance Health Jackson, Michigan  49201
Sparrow Hospital Lansing, Michigan  48912
Saint Mary Mercy Hospital Livonia, Michigan  48154
Saint Joseph Mercy Oakland Pontiac, Michigan  48341-2985
Saint Joseph Mercy Port Huron Port Huron, Michigan  48060
Saint Mary's of Michigan Saginaw, Michigan  48601
Saint John Macomb-Oakland Hospital Warren, Michigan  48093
Unity Hospital Fridley, Minnesota  55432
Saint John's Hospital - Healtheast Maplewood, Minnesota  55109
Minnesota Oncology Hematology PA-Maplewood Maplewood, Minnesota  55109
North Memorial Medical Health Center Robbinsdale, Minnesota  55422
Park Nicollet Clinic - Saint Louis Park Saint Louis Park, Minnesota  55416
Minnesota Oncology and Hematology PA-Woodbury Woodbury, Minnesota  55125
Saint Luke's Cancer Institute Kansas City, Missouri  64111
Saint Luke's Hospital of Kansas City Kansas City, Missouri  64111
Liberty Radiation Oncology Clinic Kansas City, Missouri  64116
Saint Louis-Cape Girardeau CCOP Saint Louis, Missouri  63141
Saint John's Mercy Medical Center Saint Louis, Missouri  63141
Nevada Cancer Research Foundation CCOP Las Vegas, Nevada  89106
Veterans Adminstration New Jersey Health Care System East Orange, New Jersey  07018-1095
Orange Regional Medical Center Middletown, New York  10940
Kinston Medical Specialists PA Kinston, North Carolina  28501
Doctors Hospital Columbus, Ohio  43228
Grant Medical Center Columbus, Ohio  43215
Mount Carmel Health Center West Columbus, Ohio  43222
Good Samaritan Hospital - Dayton Dayton, Ohio  45406
Dayton CCOP Dayton, Ohio  45429
Samaritan North Health Center Dayton, Ohio  45415
Blanchard Valley Hospital Findlay, Ohio  45840
Atrium Medical Center-Middletown Regional Hospital Franklin, Ohio  45005-1066
Kettering Medical Center Kettering, Ohio  45429
Marietta Memorial Hospital Marietta, Ohio  45750
Upper Valley Medical Center Troy, Ohio  45373
Saint Ann's Hospital Westerville, Ohio  43081
Genesis HealthCare System Zanesville, Ohio  43701
Harrison Bremerton Hematology and Oncology Bremerton, Washington  98310
Columbia Basin Hematology and Oncology PLLC Kennewick, Washington  99336
Minor and James Medical PLLC Seattle, Washington  98104
Swedish Medical Center-First Hill Seattle, Washington  98122-4307
Cancer Center of Kansas-Liberal Liberal, Kansas  67901
Skagit Valley Hospital Mt. Vernon, Washington  98273
Evergreen Hematology and Oncology PS Spokane, Washington  99218
Saint Luke's South Hospital Overland Park, Kansas  66213
Kansas City CCOP Prairie Village, Kansas  66208
Heartland Hematology and Oncology Associates Incorporated Kansas City, Missouri  64118
Saint Joseph Oncology Inc Saint Joseph, Missouri  64507
The Mark H Zangmeister Center Columbus, Ohio  43219
Southern Ohio Medical Center Portsmouth, Ohio  45662
Cancer Care Center at Island Hospital Anacortes, Washington  98221
Highline Medical Center-Main Campus Burien, Washington  98166
United General Hospital Sedro-Woolley, Washington  98284
Siouxland Hematology Oncology Associates Sioux City, Iowa  51101
Swedish Cancer Institute-Issaquah Issaquah, Washington  98029
Franciscan St. Francis Health Indianapolis, Indiana  46237
Southwest Oncology Group San Antonio, Texas  78245
Genesys Regional Medical Center-West Flint Campus Flint, Michigan  48532
PeaceHealth Saint Joseph Medical Center Bellingham, Washington  98225
Springfield Regional Medical Center Springfield, Ohio  45505
Saint Louis Cancer and Breast Institute-South City Saint Louis, Missouri  63109
Harrison Poulsbo Hematology and Oncology Poulsbo, Washington  98370
Idaho Urologic Institute PA Meridian, Idaho  83642
Hines Veterans Administration Hospital Hines, Illinois  60141